FINWIRES · TerminalLIVE
FINWIRES

Rollins Seen Reaffirming 2026 Outlook on Pricing Power, Customer Growth, RBC Says

By

Rollins (ROL) is expected to reaffirm its 2026 and medium-term outlook, supported by pricing power, customer wins and operational leverage across its pest-control businesses, RBC Capital Markets said Tuesday in a report.

At an investor day on Thursday, Rollins is expected to reiterate 2026 guidance of 7% to 8% organic revenue growth, 2% to 3% growth in mergers and acquisitions, and 25% to 30% adjusted incremental margins, the report said.

RBC also expects the company to restate its medium-term target for above market revenue growth, double-digit earnings growth and 30% to 35% incremental adjusted EBITDA margins.

Rollins operates in a large, underpenetrated industry with favorable pricing dynamics and is positioned to expand its customer base through its diversified brand portfolio and multichannel distribution, RBC said.

Efficiency gains from routing and scheduling optimization, back-office modernization, and other cost controls are also expected to support operational leverage, the report said.

RBC maintained its outperform rating on Rollins stock and its $67 price target.

Price: $52.50, Change: $-0.48, Percent Change: -0.92%

Related Articles

Wire

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.Gyre shares rose 1.4% in after-hours trading.

$GYRE
Wire

Evolution Petroleum Swings to Fiscal Q3 Loss as Revenue Falls; Shares Drop After Hours

Evolution Petroleum (EPM) reported a fiscal Q3 adjusted loss late Tuesday of $0.09 per diluted share, swinging from earnings of $0.02 a year earlier.Analysts polled by FactSet expected earnings of $0.02.Revenue in the three months ended March 31 fell to $20.2 million from $22.6 million a year earlier.Analysts surveyed by FactSet expected $21.3 million.Evolution shares fell 7.3% in after-hours trading.

$EPM
Wire

Arteris Q1 Adjusted Loss Narrows, Revenue Rises; Shares Gain After Hours; CFO to Retire

Arteris (AIP) reported a Q1 adjusted loss late Tuesday of $0.03 per diluted share, narrowing from the loss of $0.09 a year earlier.Four analysts polled by FactSet expected a loss of $0.07.Revenue in the three months ended March 31 rose to $22.9 million from $16.5 million a year earlier.Four analysts surveyed by FactSet expected $21 million.The company expects revenue of $23 million to $24 million in Q2 and $91 million to $95 million in the full year. Four analysts expect $22 million in Q2 and $91 million in the full year.Arteris shares rose 7.9% in after-hours trading.The company also said Chief Financial Officer Nicholas Hawkins plans to retire effective Aug. 31, and the board has started a search for a new CFO.

$AIP